Membranous nephropathy: diagnosis, treatment, and monitoring in the post-PLA2R era.
Membranous nephropathy (MN) is an immune complex-mediated cause of the nephrotic syndrome that can occur in all age groups, from infants to the very elderly. However, nephrotic syndrome in children is more frequently caused by conditions such as minimal change disease or focal segmental glomeruloscl...
| Publicado en: | Pediatric Nephrology Vol. 36; no. 1; pp. 19 - 31 |
|---|---|
| Autores principales: | , , , |
| Formato: | algorithm pictorial review tables/charts Journal Article |
| Publicado: |
Springer Nature
2021
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=147268450&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 147268450 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 0931041X EF1 jtl: Pediatric Nephrology issn: 0931041X maglogo: N pubinfo: dt: 2021 vid: 36 iid: 1 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 147268450 147268450 147268450 10.1007/s00467-019-04425-1 147268450 ppf: 19 ppct: 12 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Membranous nephropathy: diagnosis, treatment, and monitoring in the post-PLA2R era. aug: au: Safar-Boueri, Luisa Piya, Albina Beck, Laurence H. Ayalon, Rivka affil: Boston Medical Center and Boston University School of Medicine, 02118, Boston, MA, USA sug: subj: Glomerulonephritis Diagnosis Glomerulonephritis Diagnosis Glomerulonephritis Drug Therapy Rituximab Therapeutic Use Receptors, Cell Surface Blood Biological Markers Disease Surveillance Nephrotic Syndrome Etiology Autoantibodies Blood Glycoproteins Immunosuppression Immunity Child Adult Child: 6-12 years Adult: 19-44 years ab: Membranous nephropathy (MN) is an immune complex-mediated cause of the nephrotic syndrome that can occur in all age groups, from infants to the very elderly. However, nephrotic syndrome in children is more frequently caused by conditions such as minimal change disease or focal segmental glomerulosclerosis, and much less commonly by MN. While systemic conditions such as lupus or infections such as hepatitis B may more commonly be associated as secondary causes with MN in the younger population, primary or "idiopathic" MN has generally been considered a disease of adults. Autoantibodies both to the M-type phospholipase A2 receptor (PLA2R) and to thrombospondin type-1 domain-containing 7A (THSD7A), initially described in adult MN, have now been identified in children and adolescents with MN and serve as a useful diagnostic and monitoring tool in this younger population as well. Whereas definitive therapy for secondary forms of MN should be targeted at the underlying cause, immunosuppressive therapy is often necessary for primary disease. Rituximab has been successfully used in the treatment of MN, and is likely effective in children with MN as well, although dosing in the pediatric population is not well established. This review highlights the new findings in adult and pediatric MN since last reviewed in this journal. pubtype: Academic Journal doctype: algorithm pictorial review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|